Yuichiro Okushi

Yuichiro Okushi

Auto-generated profile, based on publicly available information

Yuichiro Okushi

Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute, Cleveland Clinic , 9500 Euclid Ave, Cleveland, OH 44195

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Open access
MDMilind Y. Desai
Milind Y. Desai
YOYuichiro Okushi
Yuichiro Okushi
AGAndrew Gaballa
Andrew Gaballa
QWQiuqing Wang
Qiuqing Wang
JGJeffrey B. Geske
Jeffrey B. Geske
PBP. Bajona
P. Bajona
BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy, VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) demonstrated that mavacamten reduces the need for septal reduction therapy with sustained improvement in left ventricular (LV) outflow tract gradients and symptoms. Global longitudinal strain (GLS), a measure of regional myocardial function, is a more sensitive marker of systolic function. In VALOR-HCM, we assessed serial changes in LV and right ventricular (RV) strain. METHODS: VALOR-HCM included 112 patients with symptomatic obstructive hypertrophic cardiomyopathy (mean, 60 years; 51% male; LV ejection fraction, 68%). Patients assigned to mavacamten at baseline continued the drug for 56 weeks (n=56) and those assigned to placebo (n=52) transitioned to mavacamten from weeks 16 to 56 (40-week exposure). LV-GLS and RV-GLS assessment was performed using a vendor-neutral software. Non-foreshortened apical (4-, 3-, and 2-chamber) views were used to obtain peak LV-GLS. RV focused 4-chamber view was used to calculate RV 4-chamber and free wall strain. A more negative strain value is favorable. RESULTS: At baseline, the mean LV-GLS, RV 4-chamber, and free wall strain values were −14.7%, −22.2%, and −16.8%, respectively (all worse than reported normal means). In the total study sample, LV-GLS significantly improved from baseline to week 56 ( P =0.02). Twelve patients had transient reduction in LV ejection fraction (<50%) requiring temporary drug interruption (including 3 permanent discontinuations). The LV-GLS in this subgroup was worse at baseline versus total study population (−11.4%), with no significant worsening from baseline through week 56 ( P =0.64). Both free wall and 4-chamber RV-GLS remained unchanged from baseline to week 56 ( P =0.62 and P =0.56, respectively). CONCLUSIONS: In VALOR-HCM, treatment with mavacamten improved LV-GLS from baseline through week 56 (with no significant worsening of LV-GLS in patients with a reduction in LV ejection fraction ≤50%), suggesting a favorable long-term impact on regional LV systolic function. Additionally, there was no detrimental impact on RV systolic function. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.

2 January 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
DHDiarmaid Hughes
Diarmaid Hughes
AAAli Aminian
Ali Aminian
CTChao Tu
Chao Tu
YOYuichiro Okushi
Yuichiro Okushi
YSYoshihito Saijo
Yoshihito Saijo
BXBo Xu
Bo Xu
Background: Obesity leads to an increased risk of cardiovascular disease morbidity and death, including heart failure. Bariatric surgery has been proven to be the most effective long‐term weight management treatment. This study investigated the changes in cardiac structure and function after bariatric surgery, including left ventricular global longitudinal strain. Methods and Results: There were 398 consecutive patients who underwent bariatric surgery with pre‐ and postoperative transthoracic echocardiographic imaging at a US health system between 2004 and 2019. We compared cardiovascular risk factors and echocardiographic parameters between baseline and follow‐up at least 6 months postoperatively. Along with decreases in weight postoperatively, there were significant improvements in cardiovascular risk factors, including reduction in systolic blood pressure levels from 132 mm Hg (25th–75th percentile: 120–148 mm Hg) to 127 mm Hg (115–140 mm Hg; P =0.003), glycated hemoglobin levels from 6.5% (5.9%–7.6%) to 5.7% (5.4%–6.3%; P <0.001), and low‐density lipoprotein levels from 97 mg/dL (74–121 mg/dL) to 86 mg/dL (63–106 mg/dL; P <0.001). Left ventricular mass decreased from 205 g (165–261 g) to 190 g (151–236 g; P <0.001), left ventricular ejection fraction increased from 58% (55%–61%) to 60% (55%–64%; P <0.001), and left ventricular global longitudinal strain improved from −15.7% (−14.3% to −17.5%) to −18.6% (−16.0% to −20.3%; P <0.001) postoperatively. Conclusions: This study has shown the long‐term impact of bariatric surgery on cardiac structure and function, with reductions in left ventricular mass and improvement in left ventricular global longitudinal strain. These findings support the cardiovascular benefits of bariatric surgery.

7 October 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
MDMilind Y. Desai
Milind Y. Desai
AGAndrew Gaballa
Andrew Gaballa
YOYuichiro Okushi
Yuichiro Okushi
MAMohammed Abusafia
Mohammed Abusafia
SJShada Jadam
Shada Jadam
BXBo Xu
Bo Xu
Background: Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy treated at a multihospital referral center. Methods: We included 244 patients with obstructive hypertrophic cardiomyopathy (mean age, 64 years; 57% women, 21% with atrial fibrillation, 51% New York Heart Association class III, 82% on β‐blockers) treated with mavacamten for ≥3 months (171 for ≥12 months). Serial clinical and echocardiographic assessments were performed. Results: New York Heart Association class distribution improved over time: at 3 months 21% class I, 61% class II, and 18% class III; at 12 months 36% class I, 57% class II, and 8% class III. After a mean of 1.02 years, significant improvements were observed in resting and post‐Valsalva left ventricular outflow tract gradients (−31±33 and −57±46 mm Hg), interventricular septal thickness (−1.7±4 mm), left ventricular mass index (−9.5±32 g/m 2 ), left atrial volume index (−12±13 mL/m 2 ), E/e′ (−5.5±6.4), left ventricular global longitudinal strain (1.04%±3.1%), and various left atrial and right ventricular strain measures (all P <0.05). Temporary interruption occurred in 8 patients (3.2%), and 3 (1.2%) discontinued mavacamten permanently. There were 2 noncardiac deaths, 7 heart failure admissions, 14 cases of new‐onset atrial fibrillation, and 1 patient required septal reduction therapy. At the last visit, most patients were on 5 mg (49%) or 10 mg (26%) mavacamten. Conclusions: In this real‐world cohort, mavacamten treatment was associated with sustained symptomatic and echocardiographic improvements, suggesting a favorable disease‐modifying impact with minimal need for septal reduction therapy.

1 June 2025 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
TDTiffany Dong
Tiffany Dong
HHHaroun Haroun
Haroun Haroun
AAAro Daniela Arockiam
Aro Daniela Arockiam
RKRishabh Khurana
Rishabh Khurana
JDJoseph El Dahdah
Joseph El Dahdah
TWTom Kai Ming Wang
Tom Kai Ming Wang
BACKGROUND: Aortic valve calcium score (AVCa) measured on noncontrast computed tomography (CT) is well-established for grading aortic stenosis (AS) severity. However, thresholds for AVCa measured on contrast CT remain uncertain. We evaluated correlations, associated factors, and severity thresholds of AVCa measured on contrast CT against transthoracic echocardiography (TTE) measures of AS. METHODS: Patients with native AS undergoing transcatheter aortic valve replacement evaluation from 2019 to 2020 who underwent TTE and contrast-enhanced CT were retrospectively studied (n=1035, age 79±9 years, 429 (41.5%) women, 906 (87.5%) severe and 129 (12.5%) moderate AS by TTE). AVCa was measured using the modified Agatston method with the minimum threshold of 4 SD above the mean ascending aorta blood pool Hounsfield units. Receiver-operating characteristics analysis and Youden index were used to define sex-specific optimal AVCa thresholds for identifying severe AS defined by TTE (aortic valve area by continuity equation ≤1.0 cm 2 ) in the derivation cohort and assessed when applied to the validation cohort. RESULTS: Mean aortic valve area on TTE was 0.79±0.21 cm 2 , while mean AVCa score, volume, and mass were 2152±1102 modified AU, 1853±1592 mm 3 , and 673±485 mg, respectively. Multivariable linear regression identified women to be associated with lower AVCa (β-coefficient, −358), while chronic kidney disease was associated with a higher AVCa (β-coefficient, 171). Optimal severe AS thresholds of ≥1840 modified AU for men and ≥1430 modified AU for women were determined, with area under curve (95% CIs) and sensitivities/specificities of 0.809 (0.749–0.869, 71.3%, 82.2%) for men and 0.822 (0.751–0.892), 73.4%/78.9% for women in the derivation cohort, and 0.830 (0.786–0.875), 75.9%/87.5% for men and 0.780 (0.670–0.890), 77.5%/71.4% for women in the validation cohort. CONCLUSIONS: AVCa by contrast CT is a useful tool for identifying severe AS by TTE, with sex-specific thresholds for severe AS identified. Further studies are necessary to externally validate our findings and evaluate their prognostic significance.

1 January 2025 in Cardiovascular Science
Verified
Journal Article
Open access
PDF file
AAAro Daniela Arockiam
Aro Daniela Arockiam
HKHoyek Karim
Hoyek Karim
Elio HarounElio Haroun
Elio Haroun
MVMendpara Vaidehi
Mendpara Vaidehi
GAGurram Anoop
Gurram Anoop
TWTom Kai Ming Wang
Tom Kai Ming Wang
SCIEPublish is an international open-access journal publishing service provider run by SCIE Publishing Limited, dedicated to supporting and inspiring scientists or institutions/societies who aspire to publish high-quality journals.

17 February 2026 in Journal of Echocardiography
Verified
Journal Article
Closed access
PDF file
YOYuichiro Okushi
Yuichiro Okushi
TTTomonori Takahashi
Tomonori Takahashi
KKKenya Kusunose
Kenya Kusunose